Car T Cell Therapy For Multiple Myeloma Market to witness surge, CRISPR Therapeutics, Cartesian Therapeutics, Arcellx, Novartis, companies are expected to change the Car T Cell Therapy For Multiple Myeloma Market scenario by 2032, forecasts DelveInsight.

{Delhi, India} To strategically aid Car T Cell Therapy For Multiple Myeloma companies developing drugs for Car T Cell Therapy For Multiple Myeloma, DelveInsight launched a report titled as “Car T Cell Therapy For Multiple Myeloma Market Insight Epidemiology and Market Forecast, 2032 ”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Car T Cell Therapy For Multiple Myeloma market.

Get a free sample of “Car T Cell Therapy For Multiple Myeloma Market Report” 

Car T Cell Therapy For Multiple Myeloma Market Report’s Key Highlights:

• The Car T Cell Therapy For Multiple Myeloma market size was valued approximately USD 40 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• With almost half of the 7MM's total market size in 2022, the United States had the biggest share of any country in the group.
• With a market share of almost 77% of all marketed pharmaceuticals, Argatroban had the largest market size in the United States in 2022.
• Approval of CAR-T therapies has created fresh prospects for companies concentrating on developing treatments for advanced stages of the disease, specifically the fourth line of treatment and beyond. Key players in this domain include Arcellx (CART-ddBCMA), CARsgen Therapeutics (zevorcabtagene autoleucel), Cartesian Therapeutics (Descartes-11), and various other entities.
• Key Car T Cell Therapy For Multiple Myeloma Companies: Sana Biotechnology, MedTherapy, Caribou Biosciences, Allogene Therapeutics, Nexcella, Inc., Arcellx, Inc., Yake Biotechnology, Cartesian Therapeutics, IASO Biotherapeutics, CARsgen, Arcellx, Novartis, Bristol-Myers Squibb, Poseida Therapeutics, Juno Therapeutics, and others
• Key Car T Cell Therapy For Multiple Myeloma Therapies: SC-255, MTB-003, CB-011, ALLO-715, NXC-201, CART-ddBCMA, BCMA CAR-T cells, Descartes 11, CT-103ANanjing, CT 053, CART-ddBCMA, PHE885, Orvacabtagene Autoleucel, Zevorcabtagene autoleucel (zevor-cel or CT053), P-BCMA-ALLO1, CC-95266, and others
• The Car T Cell Therapy For Multiple Myeloma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Car T Cell Therapy For Multiple Myeloma pipeline products will significantly revolutionize the Car T Cell Therapy For Multiple Myeloma market dynamics

Car T Cell Therapy For Multiple Myeloma Country based Treatment Analysis: 

The Car T Cell Therapy For Multiple Myeloma treatment market report provides treatment regimen across the 7MM. It will help companies to analyze the practices followed across 7MM, patient journey and advances in Car T Cell Therapy For Multiple Myeloma Therapies that have the potential to transform cancer treatment paradigms and improve patient outcomes.

Zevor-cel (CT053) stands as a fully human, autologous BCMA CAR T-cell therapy intended for addressing Relapsed/Refractory Multiple Myeloma (R/R MM). The New Drug Application (NDA) for zevor-cel, derived from phase I/II findings from the LUMMICAR STUDY 1 conducted in China, has been accepted by the NMPA. CARsgen is currently conducting the phase 1b/2 LUMMICAR STUDY 2 clinical trial in North America, aiming to assess the safety and effectiveness of zevor-cel for patients dealing with R/R MM within that population.

Download the report to understand which factors are driving Car T Cell Therapy For Multiple Myeloma epidemiology trends @ Car T Cell Therapy For Multiple Myeloma Epidemiology Forecast

Car T Cell Therapy For Multiple Myeloma Epidemiology Insights: 

The epidemiology section pertaining to multiple myeloma within the report includes historical and projected data segmented by various factors. These segments encompass total incident cases of multiple myeloma, symptomatic cases of multiple myeloma, gender-specific occurrences of multiple myeloma, age-specific instances of multiple myeloma, transplant eligibility in multiple myeloma cases, and the treated patient pool across all lines of therapies. This information covers the 7MM, including the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning the period from 2019 to 2032.

Car T Cell Therapy For Multiple Myeloma Epidemiology Segmentation:

• Total Prevalence of Car T Cell Therapy For Multiple Myeloma
• Prevalent Cases of Car T Cell Therapy For Multiple Myeloma by severity
• Gender-specific Prevalence of Car T Cell Therapy For Multiple Myeloma
• Diagnosed Cases of Episodic and Chronic Car T Cell Therapy For Multiple Myeloma

Within the 7MM, the United States exhibited the highest recorded incident cases of multiple myeloma in 2022, succeeded by the EU4 countries and the United Kingdom.

“Delveinsight's analysis indicates that approximately half of newly diagnosed multiple myeloma patients are not suitable candidates for transplant, and roughly a third of those who are eligible do not undergo the procedure. In the 7MM, an estimated count of 47,000 individuals newly diagnosed with multiple myeloma were ineligible for frontline transplant, while approximately 17,000 were considered eligible for transplant in 2022.”

“In terms of age-specific occurrences of Multiple Myeloma, individuals aged 65 and above represent the demographic with the highest number of cases, comprising over 70% of instances in the United States. This is followed by the age groups of 55–64 and 0–54 years.”

Car T Cell Therapy For Multiple Myeloma Therapies and Key Companies

• ALLO-715: Allogene Therapeutics
• NXC-201: Nexcella, Inc.
• CART-ddBCMA: Arcellx, Inc.
• BCMA CAR-T cells: Yake Biotechnology
• Descartes 11: Cartesian Therapeutics
• CT-103ANanjing: IASO Biotherapeutics
• CT 053: CARsgen
• CART-ddBCMA: Arcellx
• SC-255: Sana Biotechnology
• MTB-003: MedTherapy
• CB-011: Caribou Biosciences
• PHE885: Novartis
• Orvacabtagene Autoleucel: Bristol-Myers Squibb
• Zevorcabtagene autoleucel (zevor-cel or CT053): CARsgen Therapeutics
• P-BCMA-ALLO1: Poseida Therapeutics
• CC-95266: Juno T

Emerging Car T Cell Therapy For Multiple Myeloma drugs Uptake:

The management of multiple myeloma hinges on the presence of symptoms and the patient's general health condition. Typically, doctors collaborate with patients to devise an optimal treatment strategy. The objectives of treatment involve eradicating myeloma cells, regulating tumor growth, managing discomfort, and enabling patients to lead active lives. Although there isn't a definitive cure for multiple myeloma, successful management strategies often sustainably control the cancer in numerous patients over extended periods.

• In January 2023, CARsgen Therapeutics has revealed a partnership with Huadong Medicine to market zevorcabtagene autoleucel (zevor-cel), CT053, in mainland China. CT053, CARsgen's fully human, autologous BCMA CAR T-cell product candidate, is specifically designed for the treatment of relapsed/refractory multiple myeloma (R/R MM).
• In October 2022, CARsgen Therapeutics Holdings Limited revealed that China's National Medical Products Administration (NMPA) has approved the acceptance of the New Drug Application (NDA) for zevorcabtagene autoleucel ("zevor-cel," R&D code: CT053). This therapy, a fully human, autologous BCMA CAR T-cell treatment, targets relapsed and/or refractory multiple myeloma (R/R MM).

To know more about Car T Cell Therapy For Multiple Myeloma companies working in the treatment market, visit @ Car T Cell Therapy For Multiple Myeloma Clinical Trials and Therapeutic Assessment

Car T Cell Therapy For Multiple Myeloma Market Forecast:

Two CAR-T therapies have gained approval for treating Multiple Myeloma. While CAR-T treatments have displayed considerable efficacy, they also pose safety concerns like cytokine release syndrome (CRS). Initially, factors such as cost, convenience, and the time required for manufacturing might hinder the widespread adoption of CAR-T therapies. However, companies are likely to focus on minimizing side effects and accelerating manufacturing processes over time, potentially overcoming these initial obstacles.

• In the 4L+ setting, the approved CAR-T therapies (ABECMA and CARVYKTI) are projected to generate nearly USD 500 million in revenue in 2022 within the 7MM. This figure is anticipated to increase with the approval of additional emerging CAR-T therapies over the forecast period.
• The market drivers for Car T Cell Therapy For Multiple Myeloma include - Increasing prevalence of Multiple Myeloma, increase in technological advancement of CAR T-cell manufacturing in myeloma

Discover more about therapies set to grab major Car T Cell Therapy For Multiple Myeloma market share @ Car T Cell Therapy For Multiple Myeloma Treatment Market

Scope of the Car T Cell Therapy For Multiple Myeloma Market Report: 

• Geography Coverage: 7MM
• Study Period: 2019-2032
• Car T Cell Therapy For Multiple Myeloma Market Size: ~USD 400 million in 2022
• Key Car T Cell Therapy For Multiple Myeloma Companies: Mitsubishi Tanabe Pharma, Veralox Therapeutics, The Medicines Company, Canyon Pharma, and others.

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Car T Cell Therapy For Multiple Myeloma market landscape.

• Gain Competitive Edge in Indication Market : Understand the current landscape of the Car T Cell Therapy For Multiple Myeloma market, including the competitive environment, key companies developing drugs for Car T Cell Therapy For Multiple Myeloma, and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing treatment practices can help in identifying gaps and opportunities within the Car T Cell Therapy For Multiple Myeloma market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Car T Cell Therapy For Multiple Myeloma. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Car T Cell Therapy For Multiple Myeloma market with clarity and purpose.

Related Reports:

Car T Cell Therapy For Multiple Myeloma Pipeline  

"Car T Cell Therapy For Multiple Myeloma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Car T Cell Therapy For Multiple Myeloma market. A detailed picture of the Car T Cell Therapy For Multiple Myeloma pipeline landscape is provided, which includes the disease overview and Car T Cell Therapy For Multiple Myeloma treatment guidelines. 

Car T Cell Therapy For Multiple Myeloma Epidemiology 

DelveInsight's 'Car T Cell Therapy For Multiple Myeloma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Car T Cell Therapy For Multiple Myeloma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

Explore Our Success Story on Building an Interactive Competitive Intelligence Dashboard for HR+ HER2- Breast Cancer Market Landscape. Download our Oncology Competitive Intelligence Case study! 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Gaurav Bora

Email: info@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/consulting